Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Completed · Phase 1

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus gene-modified white blood cells in treating patients who have advanced ovarian epithelial cancer.

Key facts

Study ID

NCT00019136

Run by

National Cancer Institute (NCI)

Starts

1997-02-01

Last updated by the study team

2015-04-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.